Page number 47
rowth within the insulin Novo Nordisk ® insulin me 1 : 1.8% ion 2 : 48.2% 100% 80% 60% 40% 20% 0% Feb 2021 NovoMix ® 30 Combined Fast-acting insulin tMU 240 CAGR volume 1 : 4.7% 100% MI penetration 2 : 79.5% 200 80% 160 60% 120 40% 80 40 20% 0 Feb 2016 Segment volume Fiasp ® 0% Feb 2021 NovoRapid ® Combined IQVIA data collection and reporting methodology.
Page number 48
25 Investor presentation First three months of 2021 Sales growth of 7% at CER, mainl Obesity care segment Novo Nordisk reported quarterly sales DKK by therapy billion 40 35 Reported sales CAGR 1 : 7.9% 30 25 (4.5%) 1 4.4% 1 20 2.8% 1 15 9.3% 1 10 Reported sales f quarter of Rare Rare endocrine disorders Ot Biop blood disorders Obesity 1% 6% 8% care 5% 5 0 Q1 2011 Other Rare endocrine disorders Rare blood disorders Diabetes and Obesity care Q1 2021 Sales of DKK 33. 1 CAGR for 10-year period; 2 Comprises Victoza ® , Ozempic ® , Rybelsus ® ; 3 Comprises Tresiba ® , Xultophy ® and Levemir ® ; 4 Comprises Comprises NovoSeven ® , NovoEight ® , NovoThirteen ®, Refixia ® , and Esperoct ® ; 8 Comprises Norditropin ® ; 9 Primarily Vagifem ® and Ac Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 0%; Refix
